DUBLIN, Ohio, Feb. 6, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today released its Fiscal 2023 Environmental, Social and Governance (ESG) Report, highlighting the company's work toward building a healthier, more equitable future.
"At Cardinal Health, we approach ESG in a way that supports our business, positions us as a partner of choice for customers and suppliers, and ensures compliance with evolving regulatory requirements," said Jason Hollar, Cardinal Health's CEO. "We know that ESG is the right thing to do and the right thing for our business. Our new report illustrates how our ESG priorities are helping us create long-term, sustainable value for all our stakeholders."
Empowering employees
Creating value for customers and communities
Operating sustainably and responsibly
Cardinal Health's latest ESG Report was prepared in accordance with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB) and the Task Force on Climate-related Financial Disclosures (TCFD) frameworks.
Please view the full Cardinal Health Fiscal 2023 ESG Report here: CardinalHealth.com/ESGReport.
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, operations in more than 30 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.
Contacts:
Media: Erich Timmerman, This email address is being protected from spambots. You need JavaScript enabled to view it. and 614.757.8231
Investors: Matt Sims, This email address is being protected from spambots. You need JavaScript enabled to view it. and 614.553.3661
i In fiscal 2023, Cardinal Health restated its fiscal 2019 GHG emissions. These have been assured, as have fiscal 2023 emissions, as part of Cardinal Health's commitment to accurate data reporting that best represents its business. The restatement was done in part due to the addition of new activities such as emissions from biomass and refrigerants, as well as adding market-based emissions calculations for Scope 2. Additionally, some data was removed due to the divestiture of the Cordis business, and therefore properties and activities associated with that business have been removed from Cardinal Health's operational boundary.
Last Trade: | US$157.27 |
Daily Change: | 0.86 0.55 |
Daily Volume: | 1,047,836 |
Market Cap: | US$37.360B |
September 15, 2025 August 12, 2025 August 12, 2025 June 04, 2025 May 01, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load